{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:39:53Z","timestamp":1792445993483,"version":"4.5.0"},"reference-count":2,"publisher":"American College of Physicians","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.acpjournals.org\/journal\/aim\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Intern Med"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.7326\/annals-26-03622-jc","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:01:04Z","timestamp":1791234064000},"page":"JC114","source":"Crossref","is-referenced-by-count":0,"title":["In primary membranous nephropathy, obinutuzumab increased the likelihood of complete remission vs. tacrolimus at 104 wk"],"prefix":"10.7326","volume":"179","author":[{"given":"Medha","family":"Airy","sequence":"first","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA (M.A., W.C.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang C.","family":"Winkelmayer","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA (M.A., W.C.W.)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"ACP Journal Club Editorial Team at McMaster University","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4285","reference":[{"key":"ANNALS-26-03622-R1","unstructured":"Fervenza FC, Appel GB, Barbour SJ, et al; MENTOR Investigators.\n                      Rituximab or cyclosporine in the treatment of membranous nephropathy. N Engl J Med. 2019;381:36-46. [PMID: 31269364]"},{"key":"ANNALS-26-03622-R2","doi-asserted-by":"crossref","unstructured":"Su X, Wu B, Tie X, et al.\n                      Obinutuzumab as initial or second-line therapy in patients with primary membranous nephropathy. Kidney Int Rep. 2024;9:2386-2398. [PMID: 39156138]","DOI":"10.1016\/j.ekir.2024.05.004"}],"container-title":["Annals of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.acpjournals.org\/doi\/pdf\/10.7326\/ANNALS-26-03622-JC","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.acpjournals.org\/doi\/full-xml\/10.7326\/ANNALS-26-03622-JC","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:02:14Z","timestamp":1792443734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.acpjournals.org\/doi\/10.7326\/ANNALS-26-03622-JC"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":2,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.7326\/ANNALS-26-03622-JC"],"URL":"https:\/\/doi.org\/10.7326\/annals-26-03622-jc","relation":{},"ISSN":["0003-4819","1539-3704"],"issn-type":[{"value":"0003-4819","type":"print"},{"value":"1539-3704","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]}}}